Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hasmukh Jain

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Indian Journal of Cancer|August 28, 2018
Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional auditNavin Khattry, Siddhartha Laskar, Manju Sengar, et al.
Blood Cancer Journal|April 24, 2025
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib studyGaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, et al.
Blood Advances|October 31, 2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortiumJessy Xinyi Han, Min Jung Koh, Leora Boussi, et al.
British Journal of Haematology|May 1, 2025
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium studyMark N Sorial, Jessy Xinyi Han, Min Jung Koh, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Indian Journal of Cancer|August 28, 2018
Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional auditNavin Khattry, Siddhartha Laskar, Manju Sengar, et al.
Blood Cancer Journal|April 24, 2025
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib studyGaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain, et al.
Blood Advances|October 31, 2024
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortiumJessy Xinyi Han, Min Jung Koh, Leora Boussi, et al.
British Journal of Haematology|May 1, 2025
Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium studyMark N Sorial, Jessy Xinyi Han, Min Jung Koh, et al.
Pageof 8